CGTX Completes FDA Meeting, Plans Registrational Program for Zervimesine in Dementia with Lewy Bodies with Psychosis
Cognition Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $1.25
-4.8% in 3d after detection
Post-detection moves
1h
—
1d
+0.8%
3d
-4.8%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS